Adeno-Associated Virus (AAV) Versus Immune Response
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Decades ago, Friedmann and Roblin postulated several barriers to gene therapy, including tissue targeting, delivery across the blood–brain barrier (BBB), and host immune responses. These issues remain pertinent till today. Since then, several advances have been made in elucidating structures of adeno-associated virus (AAV) serotypes, antibody epitopes, and ways to modify antibody-binding sites. AAVs capsid has also been engineered to re-direct tissue tropism, reduce ubiquitination, and promote passage across the BBB. Furthermore, the use of high(er) dose recombinant AAV (rAAV) has been accompanied by a better understanding of immune responses in both experimental animals and early clinical trials, and novel work is being performed to modulate the immune response. While the immune responses to rAAV remains a major challenge in translating experimental drugs to approved medicine, and will likely require more than a single solution, we now better understand the hurdles to formulate and test experimental solutions to surmount them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Endosomal TLR9, present in Kupffer cells or DCs, particularly binds to unmethylated CpG dinucleotides in the double-stranded DNA (dsDNA) vector genomes [36].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · cited 2×
“With the exception of TLR3, all other mammalian TLRs signal through the signaling adaptor myeloid differentiation primary response gene 88 (MyD88), and this cascade leads to phosphorylation and degradation of Inhibitor of NF kappa B (IκB), thereby releasing inhibition on NF-κB and allowing it to translocate to the nuc…”
BackgroundToll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 2×
“Subsequently, it was determined to be an AAV capsid-specific CD8+ cytotoxic T cell response that likely led to the decline of factor IX expression, while other patients had preexisting humoral antibodies [22].”
BackgroundAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“When tested against two IVIG neutralization preparations, AAV-LK03 demonstrated significant levels of resistance, which is somewhat surprising considering the amount of cross-reactivity between AAV serotypes in the human population [21], and AAV2 and AAV3b in particular [20].”
BackgroundDNA shuffling of a family of genes from diverse species accelerates directed evolution
Crameri, A., Raillard, S.-A., Bermudez, E., & Stemmer, W. P. C. (1998) · Nature · doi:10.1038/34663 · Cited by 825 · cited 5×
“Coupling this reassembly with error prone PCR further increased the diversity of resulting chimeric capsids.”
BackgroundInfluentialFriedmann, T., & Roblin, R. (1972) · Science · doi:10.1126/science.175.4025.949 · Cited by 815 · cited 1×
“Friedmann and Roblin postulated several barriers to gene therapy decade ago [1].”
BackgroundWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 1×
“However, natural infection studies demonstrated existing wt AAV in human samples, and the presence of neutralizing antibodies in healthy subjects throughout the world [18,19] or in specific gene therapy target populations [20].”
BackgroundMapping of the Inducible IκB Phosphorylation Sites That Signal Its Ubiquitination and Degradation†
Didonato, J., Mercurio, F., Rosette, C., Wu-Li, J., Suyang, H., Ghosh, S., & Karin, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1295 · Cited by 707 · cited 1×
“In the case of I Kappa B degradation, serine phosphorylation is the key modification leading to ubiquitination [41].”
BackgroundGrimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Cited by
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
“These topics were discussed in depth in recent reviews (Colella et al., 2017; Domenger and Grimm, 2019; Rabinowitz et al., 2019; Verdera et al., 2020; Wang et al., 2019).”
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Self-citationViral vector‐based gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269
Exosome-mediated delivery of gene vectors for gene therapy
Duan, L., Xu, L., Xu, X., Qin, Z., Zhou, X., Xiao, Y., Liang, Y., & Xia, J. (2021) · Nanoscale · doi:10.1039/d0nr07622h · Cited by 238
Overcoming innate immune barriers that impede AAV gene therapy vectors
Muhuri, M., Maeda, Y., Ma, H., Ram, S., Fitzgerald, K. A., Tai, P. W. L., & Gao, G. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143780 · Cited by 212
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
Salabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173510 · Cited by 159
“…AAV are recognized via the adaptor proteins, Toll-like receptors (TLRs), primarily TLR2 and TLR9, which can trigger an innate immune response and promote the activation of adaptive immunity through activation of cytokines and interferons (IFNs) that in turn activate CD8 + T cells (8, 12, 14, 15).”
BackgroundExtracellular vesicles: Emerging tools as therapeutic agent carriers
Liu, S., Wu, X., Chandra, S., Lyon, C. J., Ning, B., Jiang, L., Fan, J., & Hu, Y. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.002 · Cited by 158
Novel AAV capsids for intravitreal gene therapy of photoreceptor disorders
Pavlou, M., Schön, C., Occelli, L. M., Rossi, A., Meumann, N., Boyd, R. F., Bartoe, J. T., Siedlecki, J., Gerhardt, M. J., Babutzka, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013392 · Cited by 135
“With regard to the eye, only a transient immune response to intraocular vector delivery has been observed so far, which did not limit treatment success (Reichel et al, 2018; Rabinowitz et al, 2019).”
BackgroundGM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
Leal, A. F., Benincore-Flórez, E., Solano-Galarza, D., Garzón Jaramillo, R. G., Echeverri-Peña, O. Y., Suarez, D. A., Alméciga-Díaz, C. J., & Espejo-Mojica, A. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176213 · Cited by 138
AAV integration in human hepatocytes
Dalwadi, D. A., Calabria, A., Tiyaboonchai, A., Posey, J., Naugler, W. E., Montini, E., & Grompe, M. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.031 · Cited by 126
Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes
Hamilton, B. A., & Wright, J. F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675897 · Cited by 117
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M. (2020) · Brain Sciences · doi:10.3390/brainsci10020119 · Cited by 112
Self-citationManso, A. M., Hashem, S. I., Nelson, B. C., Gault, E., Soto-Hermida, A., Villarruel, E., Brambatti, M., Bogomolovas, J., Bushway, P. J., Chen, C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax1744 · Cited by 86
Towards the optical cochlear implant: optogenetic approaches for hearing restoration
Dieter, A., Keppeler, D., & Moser, T. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201911618 · Cited by 105
“…clinical gene therapy studies, mostly using systemic AAV application, have reported problems, highlighting the importance to perform biosafety studies for each individual virus, transgene, titer, and administration route (Hin-derer et al , 2018; Hordeaux et al , 2018; Rabinowitz et al , 2019).”
Hearing of Otof-deficient mice restored by trans-splicing of N- and C-terminal otoferlin
Tang, H., Wang, H., Wang, S., Hu, S. W., Lv, J., Xun, M., Gao, K., Wang, F., Chen, Y., Wang, D., et al. (2022) · Human Genetics · doi:10.1007/s00439-022-02504-2 · Cited by 89
Chen, W., Yao, S., Wan, J., Tian, Y., Huang, L., Wang, S., Akter, F., Wu, Y., Yao, Y., & Zhang, X. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.029 · Cited by 83
Wright, J. F. (2021) · Biotechnology Journal · doi:10.1002/biot.202000022 · Cited by 82
Evading and overcoming AAV neutralization in gene therapy
Earley, J., Piletska, E. V., Ronzitti, G., & Piletsky, S. A. (2022) · Trends in biotechnology · doi:10.1016/j.tibtech.2022.11.006 · Cited by 93
Recent advances in gene therapy for neurodevelopmental disorders with epilepsy
Turner, T. J., Zourray, C., Schorge, S., & Lignani, G. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15168 · Cited by 71
“However, even AAV9, one of the most BBB permeable capsids, only crosses the BBB modestly when administered systemically in perinatal and neonatal rodents, non-human primates and humans (Mattar et al. 2013; Rahim et al. 2011).”
BackgroundMonosynaptic Tracing Success Depends Critically on Helper Virus Concentrations
Lavin, T. K., Jin, L., Lea, N. E., & Wickersham, I. R. (2020) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2020.00006 · Cited by 67
Fischell, J. M., & Fishman, P. S. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.747726 · Cited by 67
Kiourtis, C., Wilczynska, A., Nixon, C., Clark, W. A., May, S., & Bird, T. G. (2021) · Biology Open · doi:10.1242/bio.058678 · Cited by 74
“They elicit a very mild immune response, especially the recombinant AAV vectors (rAAVs) that have undergone modifications to partly evade the immune system (Rogers et al., 2011; Rabinowitz et al., 2019).”
BackgroundDrug Delivery to the Brain: Recent Advances and Unmet Challenges
Bhunia, S., Kolishetti, N., Vashist, A., Yndart, A., Brooks, D., & Nair, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15122658 · Cited by 77
“Despite the shortcomings of strict packaging limit (~4.7 kb) [173] and pre-existing immunity in certain serotypes [174], the transduction efficacy and tolerability [175,176] of some serotypes, e.g., AAV9, AAV2 have affirmed their emerging exploration in different pre-clinical CNS disease models [177].”
BackgroundInfluentialInnate Immune Response to Viral Vectors in Gene Therapy
Wang, Y., & Shao, W. (2023) · Viruses · doi:10.3390/v15091801 · Cited by 66
A comprehensive atlas of AAV tropism in the mouse
Walkey, C. J., Snow, K. J., Bulcha, J., Cox, A. R., Martinez, A. E., Ljungberg, M. C., Lanza, D. G., Giorgi, M. D., Chuecos, M. A., Alves‐Bezerra, M., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.041 · Cited by 68
Lentz, J. J., Pan, B., Ponnath, A., Tran, C. M., Nist-Lund, C. A., Galvin, A., Goldberg, H., Robillard, K. N., Jodelka, F. M., Farris, H. E., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.08.002 · Cited by 56
“Second, while 20-O-methoxyethyl (20-MOE) ASOs have been shown in limited studies to activate the innate immune response when delivered systemically long-term on a weekly basis,(40,41) they do not elicit an adaptive immune response and thus can be repeatedly dosed, unlike AAV therapeutics.(42,43) In this study, we obse…”
BackgroundApplying machine learning to predict viral assembly for adeno-associated virus capsid libraries
Marques, A. D., Kummer, M., Kondratov, O., Banerjee, A., Moskalenko, O., & Zolotukhin, S. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.11.017 · Cited by 55
Chan, Y. K., Dick, A. D., Hall, S. M., Langmann, T., Scribner, C. L., Mansfield, B. C., & for the Ocular Gene Therapy Inflammation Working Group (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.4.3 · Cited by 56
Self-citationBurdett, T., & Nuseibeh, S. (2022) · Gene Therapy · doi:10.1038/s41434-022-00363-0 · Cited by 61
Chandler, L. C., Barnard, A. R., Caddy, S. L., Patrício, M. I., McClements, M. E., Fu, H., Rada, C., MacLaren, R. E., & Xue, K. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.012 · Cited by 50
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
“Nonetheless, AAV-specific immune responses have been observed, which may induce potentially harmful inflammatory reactions and compromise the outcome of gene therapy [8].”
BackgroundHuang, L., Wan, J., Wu, Y., Tian, Y., Yao, Y., Yao, S., Ji, X., Wang, S., Su, Z., & Xu, H. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119142 · Cited by 48
Xu, L., Yao, S., Ding, Y. E., Xie, M., Feng, D., Sha, P., Tan, L., Bei, F., & Yao, Y. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05661-2 · Cited by 48
“The TLR9 receptor is essential for the recognition of unmethylated CpG motifs, which are highly present in ITR region [15].”
BackgroundFleischer, A., Vallejo‐Díez, S., Martín‐Fernández, J. M., Sánchez‐Gilabert, A., Castresana, M., del Pozo, Á., Esquisabel, A., Ávila, S., Castrillo, J. L., Gaínza, E., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.005 · Cited by 56
Treating Parkinson’s disease by astrocyte reprogramming: Progress and challenges
Wei, Z. D., & Shetty, A. K. (2021) · Science Advances · doi:10.1126/sciadv.abg3198 · Cited by 54
Chen, X., Dong, T., Hu, Y., Pace, R. D., Mattera, R., Eberhardt, K., Ziegler, M., Pirovolakis, T., Şahin, M., Bonifacino, J. S., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci164575 · Cited by 49
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 47
“get cell, and expression of immune-stimulating cytokines that allow for a robust adaptive immune response.(62) In the clinic, patients’ cytokine levels are routinely”
Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns
Pierce, G. F. (2020) · Haemophilia · doi:10.1111/hae.14023 · Cited by 39
Adeno‐associated virus (AAV)-based gene therapy for glioblastoma
Xu, X., Chen, W., Zhu, W., Chen, J., Ma, B., Ding, J., Wang, Z., Li, Y., Wang, Y., & Zhang, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01776-4 · Cited by 49
Genetic-Based Approaches to Inherited Metabolic Liver Diseases
Zabaleta, N., Hommel, M., Salas, D., & González‐Aseguinolaza, G. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.140 · Cited by 36
“60,61 Furthermore, studies performed in mice with humanized livers and nonhuman primates revealed important differences in the transduction ef-ficiency of the different AAV serotypes between human/NHP and murine hepatocytes.”
Hadi, M., Allela, O. Q. B., Jabari, M., Jasoor, A. M., Naderloo, O., Yasamineh, S., Gholizadeh, O., & Kalantari, L. (2024) · Virology Journal · doi:10.1186/s12985-024-02286-1 · Cited by 37
“Although AAV treatments have generally exhibited a commendable safety record in human applications, ongoing endeavors to assess both short-term and long-term safety profiles for AAV vectors remain imperative [174].”
BackgroundGene Therapy for Genetic Syndromes: Understanding the Current State to Guide Future Care
Henderson, M. L., Zieba, J. K., Li, X., Campbell, D. B., Williams, M. R., Vogt, D. L., Bupp, C. P., Edgerly, Y. M., Rajasekaran, S., Hartog, N., et al. (2024) · BioTech · doi:10.3390/biotech13010001 · Cited by 41
“Levels of pre-existing antibodies for AAVs have been noted to be high enough to reduce the patient inclusion population for clinical trials by almost 50% [106].”
BackgroundZhan, W., Muhuri, M., Tai, P. W. L., & Gao, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.673699 · Cited by 37
Therapeutic Strategies For Tay-Sachs Disease
Picache, J. A., Zheng, W., & Chen, C. Z. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.906647 · Cited by 40
Efficacy of AAV9-mediated SGPL1 gene transfer in a mouse model of S1P lyase insufficiency syndrome
Zhao, P., Tassew, G., Lee, J. Y., Oskouian, B., Muñoz, D. P., Hodgin, J. B., Watson, G. L., Tang, F., Wang, J., Luo, J., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.145936 · Cited by 36
Gene Transfer Therapy for Neurodevelopmental Disorders
Özlü, C., Bailey, R. M., Sinnett, S. E., & Goodspeed, K. (2021) · Developmental Neuroscience · doi:10.1159/000515434 · Cited by 34
Meng, Y., Sun, D., Qin, Y., Dong, X., Luo, G., & Liu, Y. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.02.019 · Cited by 33
A comparison of AAV-vector production methods for gene therapy and preclinical assessment
Davidsson, M., Negrini, M., Hauser, S., Svanbergsson, A., Lockowandt, M., Tomasello, G., Manfredsson, F. P., & Heuer, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-78521-w · Cited by 31
Hutt, J. A., Assaf, B. T., Bolon, B. N., Cavagnaro, J. A., Galbreath, E. J., Grubor, B., Kattenhorn, L. M., Romeike, A., & Whiteley, L. O. (2021) · Toxicologic Pathology · doi:10.1177/01926233211041962 · Cited by 28
López-Astacio, R. A., Adu, O. F., Lee, H., Hafenstein, S. L., & Parrish, C. R. (2023) · Journal of Virology · doi:10.1128/jvi.00161-23 · Cited by 30
Shmidt, A. A., & Egorova, T. V. (2021) · Pharmaceuticals · doi:10.3390/ph15010023 · Cited by 30
The Landscape of Early Clinical Gene Therapies outside of Oncology
Rittié, L., Athanasopoulos, T., Calero-Garcia, M., Davies, M. L., Dow, D. J., Howe, S. J., Morrison, A., Ricciardelli, I., Saudemont, A., Jespers, L. S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.09.002 · Cited by 26
Neurosurgical gene therapy for central nervous system diseases
Patel, R. V., Nanda, P., & Richardson, R. M. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2024.e00434 · Cited by 23
“Several hypotheses have been proposed to explain this fi nding, including differential patterns of human cell targeting, immune response to viral capsids, and variability in gene transduction ef fi ciency [17,18].”
BackgroundDownstream processing of AAV based gene therapy vectors
Jungbauer, A., & Wheelwright, S. M. (2025) · Separation and Purification Technology · doi:10.1016/j.seppur.2025.133051 · Cited by 32
AAV-Based Gene Therapy: Opportunities, Risks, and Scale-Up Strategies
Moldavskii, D., Gilazieva, Z., Fattakhova, А. N., Solovyeva, V. V., Issa, S. S., Sufianov, A. A., Суфианова, Г. З., & Rizvanov, A. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178282 · Cited by 28
“After transduction, some AAV virions undergo ubiquitination and degradation in proteasomes, and their capsid peptides bind to MHC class I molecules, which are transported to the cell surface for antigen presentation, leading to the destruction of transduced cells by cytotoxic T cells [60].”
Neuronal Replenishment via Hydrogel-Rationed Delivery of Reprogramming Factors
Mahmoudi, N., Wang, Y., Moriarty, N., Ahmed, N. Y., Dehorter, N., Lisowski, L., Harvey, A. R., Parish, C. L., Williams, R. J., & Nisbet, D. R. (2024) · ACS Nano · doi:10.1021/acsnano.3c11337 · Cited by 25
Xie, B., Wang, X., Pan, Y., Jiang, G., Feng, J., & Lin, Y. (2020) · Theranostics · doi:10.7150/thno.46992 · Cited by 24
“It has been reported that systemically delivered viral vectors can trigger host immune responses to the viral capsid and the transgene products [38,39].”
BackgroundRescue of a familial dysautonomia mouse model by AAV9-Exon-specific U1 snRNA
Romano, G., Riccardi, F., Bussani, E., Vodret, S., Licastro, D., Ragone, I., Ronzitti, G., Morini, E., Slaugenhaupt, S., & Pagani, F. (2022) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2022.07.004 · Cited by 24
Abulimiti, A., Lai, M. S., & Chang, R. C. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111549 · Cited by 23
Chen, M., Kim, B., Jarvis, M., Fleury, S., Deng, S., Nouraein, S., Butler, S. S., Lee, S., Chambers, C., Hodges, H. C., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00371-0 · Cited by 20
Biology, Pathobiology and Gene Therapy of CNG Channel-Related Retinopathies
Gerhardt, M. J., Priglinger, S. G., Biel, M., & Michalakis, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020269 · Cited by 26
Modulation of P2Y6R expression exacerbates pressure overload-induced cardiac remodeling in mice
Shimoda, K., Nishimura, A., Sunggip, C., Ito, T., Nishiyama, K., Kato, Y., Tanaka, T., Tozaki‐Saitoh, H., Tsuda, M., & Nishida, M. (2020) · Scientific Reports · doi:10.1038/s41598-020-70956-5 · Cited by 21
Bara-Ledesma, N., Viteri-Noël, A., Rodriguez, M. L., Stamatakis, K., Fabregate, M., Vazquez-Santos, A., & del Olmo, V. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020578 · Cited by 23
Genetically Engineering the Nervous System with CRISPR-Cas
Sandoval, A., Elahi, H., & Ploski, J. E. (2020) · eNeuro · doi:10.1523/eneuro.0419-19.2020 · Cited by 19
“Host anti-vector and transgene responses are discussed elsewhere (Sun et al., 2003; Rabinowitz et al., 2019; Wang et al., 2019).”
BackgroundFactor IX-Padua AAV gene therapy in hemophilia B: phases 1/2 and 3 trials
Xue, F., Ju, M., Zhu, T., Zhou, Z., Sun, J., Yang, L., Yan, Z., Zhou, H., Du, X., Zheng, C., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-04012-y · Cited by 23
Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness
Chattopadhyay, A., Jailani, A. A. K., & Mandal, B. (2023) · Vaccines · doi:10.3390/vaccines11081347 · Cited by 16
Gene Therapy for Inherited Retinal Disorders: Update on Clinical Trials
Michalakis, S., Gerhardt, M. J., Rudolph, G., Priglinger, S. G., & Priglinger, C. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1384-0818 · Cited by 19
“7 kb single-stranded DNA (ssDNA) genome containing two genes, Rep and Cap, between two inverted terminal repeats (ITRs) [10].”
BackgroundCurrent Advances in Adeno-Associated Virus-Mediated Gene Therapy to Prevent Acquired Hearing Loss
Wu, F., Sambamurti, K., & Sha, S. (2022) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-022-00866-y · Cited by 16
“One may use several paradigms to limit acquired AAV immunity, such as using single-dose delivery methods or changing the AAV serotype for repeat delivery [72].”
BackgroundEmerging optogenetics technologies in biomedical applications
Ren, H., Cheng, Y., Wen, G., Wang, J., & Zhou, M. (2023) · Smart Medicine · doi:10.1002/smmd.20230026 · Cited by 16
Shin, H. Y., Choi, H., Kim, N., Park, N., Kim, H., Kim, J., & Kim, Y. B. (2020) · Genes · doi:10.3390/genes11111306 · Cited by 14
Mucopolysaccharidosis type IIIB: a current review and exploration of the AAV therapy landscape
Rouse, C. J., Jensen, V. N., & Heldermon, C. D. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.377606 · Cited by 16
“These receptors trigger a signaling cascade that initiates the response and activation of the innate immune system (Rabinowitz et al., 2019).”
Role of Essential Metal Ions in AAV Vector-Mediated Transduction
Rambhai, H. K., Ashby, F. J., Qing, K., & Srivastava, A. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.019 · Cited by 11
Utilization of ethanolamine phosphate phospholyase as a unique astrocytic marker
Tsujioka, H., & Yamashita, T. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1097512 · Cited by 5
“Although the immunogenicity of AAV is thought to be low, some immune responses are known to be induced by AAV infection (Rabinowitz et al., 2019).”
BackgroundMultiplex gene editing reduces oxalate production in primary hyperoxaluria type 1
Zheng, R., 上海交通大学医学院附属新华医院, 上. 2., Zhang, D.-X., Shao, Y., Fang, X., Yang, L., Huo, Y.-N., Li, D., Geng, H., 华东师范大学, 上. 2., et al. (2023) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2022.495 · Cited by 12
Astrocytes, a Promising Opportunity to Control the Progress of Parkinson’s Disease
Sánchez, A., Moráles, I., Rodriguez‐Sabate, C., Solé-Sabater, M., & Rodríguez, M. (2021) · Biomedicines · doi:10.3390/biomedicines9101341 · Cited by 14
Iroanya, G. I., Subramanyam, P. N., Wells, K. D., & Green, J. A. (2025) · Human Gene Therapy · doi:10.1177/10430342251378524 · Cited by 11
Advanced Gene Therapy Strategies for the Repair of ACL Injuries
Amini, M., Venkatesan, J. K., Liu, W., Leroux, A., Nguyễn, T. N., Madry, H., Migonney, V., & Cucchiarini, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214467 · Cited by 13
Gene therapy using Aβ variants for amyloid reduction
Park, K., Wood, C. A., Li, J., Taylor, B. C., Oh, S.-W., Young, N. L., & Jankowsky, J. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.026 · Cited by 12
Cui, M., Lü, Y., Tang, C., Zhang, R., Wang, J., Yang, S., Cheng, S., & Ding, W. (2019) · Molecules · doi:10.3390/molecules24213973 · Cited by 11
“The advantages of of AAV-based vectors include their demonstrated safety due to their non-pathogenecity and their ability to maintain long-term gene expression [4,5].”
BackgroundPlanet of the AAVs: The Spinal Cord Injury Episode
Štěpánková, K., Jendelová, P., & Urdzíková, L. M. (2021) · Biomedicines · doi:10.3390/biomedicines9060613 · Cited by 10
“It is suggested that the immune reaction could be reduced by CpG depletion [81,82].”
BackgroundApplication of Viruses for Gene Therapy and Vaccine Development
Lundstrom, K. H. (2022) · Advances in environmental microbiology · doi:10.1007/978-3-030-85395-2_9 · Cited by 9
Huang, F., Ren, M., Pei, J., Mei, H., Sui, B., Wu, Q. D., Chai, B., Yang, R., Zhou, M., Fu, Z. F., et al. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.702273 · Cited by 8
Handyside, B., Zhang, L., Yates, B., Xie, L. Y., Ismail, A. M., Murphy, R., Baridon, B., Su, C., Bouwman, T., Mangini, L., et al. (2023) · Human Gene Therapy · doi:10.1089/hum.2023.065 · Cited by 7
Huang, Y., Zhu, W., Zhou, J., Huang, Q., & Zeng, G. (2024) · Biomolecules · doi:10.3390/biom14050511 · Cited by 10
“Due to the significant drawbacks, such as off-target effects, challenges in delivery efficiency, high-dose toxicity and the activation of host immune responses, CRISPR/Cas9 technology is currently confined to preclinical trials in vitro cell cultures and animal models [147–149].”
BackgroundCai, X., Zhang, X., & Bai, H. (2020) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/ypgx4 · Cited by 6
Culture of Human Retinal Explants for Ex Vivo Assessment of AAV Gene Delivery
Wu, W.-H., Tso, A., Breazzano, M. P., Jenny, L. A., Levi, S. R., Tsang, S. H., & Quinn, P. M. J. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2651-1_28 · Cited by 6
Masri, S., Carré, L., Jaulin, N., Vandamme, C., Couzinié, C., Guy‐Duché, A., Dupont, J.-B., Pereira, A., Charpentier, É., David, L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310447 · Cited by 6
Chen, X., Luo, J., Song, M., Pan, L., Qu, Z., Huang, B., Yu, S., & Shu, H. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1342366 · Cited by 7
“Primary challenges involve addressing the immunogenicity (Rapti et al., 2012; Rabinowitz et al., 2019) and the inconsistencies in intracranial transduction efficiency (Foust et al., 2009; Gray et al., 2013) associated with these vectors.”
BackgroundResearch Status and Applications of Adeno‐Associated Virus
Xia, K., Liu, S., Wu, Z., & Jiang, J. (2024) · ChemBioChem · doi:10.1002/cbic.202400856 · Cited by 4
Liu, Y., Liang, F., Zhang, R., Tang, C., Li, X., Wang, Y., He, Z., & Liu, H. (2025) · Materials Horizons · doi:10.1039/d5mh00203f · Cited by 4
Gu, W., Shi, Q., Wang, L., Zhang, J., Yuan, G.-F., Chen, S., Zuo, Y., & Fan, J. (2020) · Archives of Virology · doi:10.1007/s00705-020-04709-0 · Cited by 4
Colon‐Moran, W., Baer, A., Lamture, G., Stapleton, J. T., Fischer, J. W., & Bhattarai, N. (2021) · Gene Therapy · doi:10.1038/s41434-021-00302-5 · Cited by 4
“Many preclinical and clinical studies have demonstrated activation of both the innate and the adaptive immune responses during gene therapy with common viral vectors derived from AAV, adenovirus, and lentivirus 7–10 .”
BackgroundSuárez-Herrera, N., Riswick, I. B., Vázquez-Domínguez, I., Duijkers, L., Karjosukarso, D. W., Piccolo, D., Bauwens, M., Baere, E. B. W. D., Cheetham, M. E., Garanto, A., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.019 · Cited by 5
Gene Therapy Today and Tomorrow
Lundstrom, K. H. (2019) · Diseases · doi:10.3390/diseases7020037 · Cited by 7
Dou, D., Lu, J., Chen, X., & Zhang, X. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03931-2 · Cited by 4
“Instances of this toxicity encompass hepatic impairment subsequent to systemic administration or inflammatory responses arising from localized administration to the brain [42, 43].”
Xiao-ping, H., Wang, X., Sun, Y., Xie, X., Xiao, L., Xu, Y., Yan, Q., Xu, X., Li, L., Xu, W., et al. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70308 · Cited by 3
Design principles for optogenetic-based targeted protein degradation
Chen, Y., Wang, S., Xie, L., Zhang, L., Zhu, M., & Xu, Y. (2025) · Synthetic and Systems Biotechnology · doi:10.1016/j.synbio.2025.12.006 · Cited by 2
“Nevertheless, host immune responses and strict payload constraints ( 5 kb) constrain its utility [120,121].”
Metadata
- Authors
- Rabinowitz, J., Chan, Y. K., & Samulski, R. J.
- Affiliations
- Pfizer (United States) (US)
- Harvard University (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Rabinowitz, Joseph
- Chan, Ying Kai
- Samulski, Richard Jude
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2019-01-25
- Volume
- 11
- Issue
- 2
- Pages
- 102
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC6409805
- OpenAlex
- W2911711918
- Cited by
- 122
- References
- 54
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 14 · 2023: 16 · 2022: 17 · 2021: 29 · 2020: 24 · 2019: 6
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Heart, Lung, and Blood Institute (P01HL112761)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, recombinant adeno-associated virus, gene therapy, immune response, AAV serotypes, capsid engineering, antibody epitopes, tissue tropism, blood-brain barrier, ubiquitination, immunomodulation, clinical translation
- MeSH terms
- Host Microbial Interactions, Dependovirus, Animals, Clinical Trials as Topic, Genetic Vectors, Humans, Immunity, Innate, Parvoviridae Infections, Genetic Therapy, Capsid Proteins, Mice, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.